Relevant bibliographies by topics / Hypotensive agents – Pharmacokinetics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Hypotensive agents – Pharmacokinetics'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hypotensive agents – Pharmacokinetics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hypotensive agents – Pharmacokinetics"

1

Misra, Debashish, Arthur Frankel, Philip Hall, et al. "The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML)." Blood 104, no. 11 (2004): 4513. http://dx.doi.org/10.1182/blood.v104.11.4513.4513.

Full text
Abstract:
Abstract Background: Although complete remission rates for AML are near 70% with combination induction and consolidation chemotherapy, most patients will relapse and die from the disease or treatment complications. New agents with unique mechanisms are needed. One such class of therapeutics are fusion proteins consisting of protein synthesis inactivating peptide toxins fused to tumor cell selective ligands. DT388-IL3 is one such fusion protein. Rationale: In preclinical studies, DT388-IL3 was cytotoxic to the IL3 receptor expressing leukemia cell lines but not toxic to IL3 receptor negative ce
APA, Harvard, Vancouver, ISO, and other styles
2

Baidas, Said M., Eric P. Winer, Gini F. Fleming, et al. "Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer." Journal of Clinical Oncology 18, no. 14 (2000): 2710–17. http://dx.doi.org/10.1200/jco.2000.18.14.2710.

Full text
Abstract:
PURPOSE: To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 200 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pretreated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. RESULTS: No patient had a true partial or compl
APA, Harvard, Vancouver, ISO, and other styles
3

Clark, Justin A., and David S. Burgess. "Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance." Therapeutic Advances in Infectious Disease 7 (January 2020): 204993612095260. http://dx.doi.org/10.1177/2049936120952604.

Full text
Abstract:
Objective: To review the mechanism of action, mechanisms of resistance, in vitro activity, pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. Data sources: A PubMed search was performed from January 2006 to August 2019 using the following search terms: plazomicin and ACHN-490. Another search was conducted on clinicaltrials.gov for published clinical data. References from selected studies were also used to find additional literature. Study selection and data extraction: All English-language studies presenting original research ( in vitro, in vivo, pharmacokinetic,
APA, Harvard, Vancouver, ISO, and other styles
4

McPherson, Christopher. "Premedication for Endotracheal Intubation in the Neonate." Neonatal Network 37, no. 4 (2018): 238–47. http://dx.doi.org/10.1891/0730-0832.37.4.238.

Full text
Abstract:
Endotracheal intubation, a common procedure in neonatal intensive care, results in distress and disturbs physiologic homeostasis in the newborn. Analgesics, sedatives, vagolytics, and/or muscle relaxants have the potential to blunt these adverse effects, reduce the duration of the procedure, and minimize the number of attempts necessary to intubate the neonate. The medical care team must understand efficacy, safety, and pharmacokinetic data for individual medications to select the optimal cocktail for each clinical situation. Although many units utilize morphine for analgesia, remifentanil has
APA, Harvard, Vancouver, ISO, and other styles
5

Nutt, D. "Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70250-0.

Full text
Abstract:
Receptor-binding profiles of antipsychotics differ, with important implications for treatment efficacy and tolerability. Receptors implicated in clinical response and adverse effects include dopamine D2, serotonin 5HT1A and 5HT2A, as well as H1 histamine, M1 muscarinic and alpha1 adrenergic receptors. Varying receptor affinities can explain the clinical profile specific to each compound, including adverse events such as weight gain, metabolic disturbance, hypotension, hyperprolactinaemia and extrapyramidal symptoms.Receptor profiles also play a role when switching between antipsychotics. Consi
APA, Harvard, Vancouver, ISO, and other styles
6

Papandreou, Christos N., Danai D. Daliani, Darrell Nix, et al. "Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer." Journal of Clinical Oncology 22, no. 11 (2004): 2108–21. http://dx.doi.org/10.1200/jco.2004.02.106.

Full text
Abstract:
PurposeTo determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa).Patients and MethodsFifty-three patients (48 with AIPCa) received 128 cy
APA, Harvard, Vancouver, ISO, and other styles
7

Demczar, Dorothy, and Gary M. Levin. "Use of Atypical Antipsychotics on an As-Needed Basis." Journal of Pharmacy Technology 12, no. 4 (1996): 145–48. http://dx.doi.org/10.1177/875512259601200407.

Full text
Abstract:
Objective: To review the literature and determine whether atypical antipsychotics should be used on an as-needed (prn) basis. Data Sources: Pertinent English-language literature dealing with atypical antipsychotics, typical antipsychotics, phamacokinetics, and prn dosing strategies was retrieved from a MEDLINE search (1960–1995). Data Extraction: Articles that discussed either pharmacokinetic parameters or the rationale for using antipsychotics on a prn basis. Data Synthesis: Administration of typical antipsychotics on a prn basis, either alone or in combination with scheduled antipsychotics,
APA, Harvard, Vancouver, ISO, and other styles
8

Markowitz, John S., Barbara G. Wells, and William H. Carson. "Interactions Between Antipsychotic and Antihypertensive Drugs." Annals of Pharmacotherapy 29, no. 6 (1995): 603–9. http://dx.doi.org/10.1177/106002809502900610.

Full text
Abstract:
Objective: To provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensives and to provide recommendations for the selection of antihypertensives in patients receiving antipsychotic therapy. Data Sources: A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports. Study Selection: All available sources were reviewed. Data Extraction: Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinen
APA, Harvard, Vancouver, ISO, and other styles
9

Lee, Jeeyun, Young Suk Park, James Burke, et al. "Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 3608. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3608.

Full text
Abstract:
3608^ Background: Pexa-Vec is an EGFR-targeted vaccinia virus engineered to express granulocyte-macrophage colony stimulating factor (GM-CSF), thereby stimulating direct oncolysis, tumor vascular disruption and anti-tumor immunity (Nat Rev Cancer 2009). Dose-dependent IV Pexa-Vec delivery was defined previously (Nature2011). This study was designed to assess the safety, maximal tolerated dose and anti-tumor activity of Pexa-Vec administered IV in patients with mCRC after failure of standard therapies. Methods: Nine patients were treated at 1 of 3 dose levels (106, 107 or 3x107pfu/kg IV every 2
APA, Harvard, Vancouver, ISO, and other styles
10

Ahmad, Razi, Anwar Habib, and Sana Rehman. "Efficacy of various antihypertensive drugs in the treatment of hypertension in the patients of end-stage renal disease leading to hemodialysis: a retrospective study." International Journal of Advances in Medicine 4, no. 1 (2017): 203. http://dx.doi.org/10.18203/2349-3933.ijam20170112.

Full text
Abstract:
Background: Cardiovascular complications are the leading cause of morbidity and mortality in the patients of end-stage renal disease leading to hemodialysis. Majority of these patients suffers from hypertension and adequate control of blood pressure is a challenge in these patients because of multifactorial etiology and complicated pharmacokinetic changes in these patients. The present study aims is to find out the best possible drug or combination of drugs that can provide better control of blood pressure and improve the quality of life of these patients.Methods: A retrospective study was car
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hypotensive agents – Pharmacokinetics"

1

Khamanga, Sandile Maswazi Malungelo. "Formulation and evaluation of captopril loaded polymethacrylate and hydroxypropyl methycellulose microcapsules." Thesis, Rhodes University, 2010. http://hdl.handle.net/10962/d1013443.

Full text
Abstract:
Angiotensin-converting enzyme (ACE) inhibitors are some of the most commonly prescribed medications for hypertension. They are cited in many papers as the treatment most often recommended by guidelines and favoured over other antihypertensive drugs as first-line agents especially when other high-risk conditions are present, such as diabetic nephropathy. The development of captopril (CPT) was amongst the earliest successes of the revolutionary concept of structure-based drug design. Due to its relatively poor pharmacokinetic profile or short half-life of about 1 hour, the formulation of sustain
APA, Harvard, Vancouver, ISO, and other styles
2

Farid, Samar Farghali. "Development and in vivo testing of novel hydrochlorothiazide gastric retention formulations in healthy volunteers and stage I hypertensive patients." Thesis, 2004. http://hdl.handle.net/1957/30488.

Full text
Abstract:
This thesis describes in vitro and in vivo evaluation of a gastric retention formulation (GRF) developed at Oregon State University. The formulation was prepared from xanthan gum and locust bean gum as gelling agents and other formulation ingredients were added, then it was originally vacuum oven dried. The effect of freeze drying on GRF was studied in this research. Freeze dried GRF were evaluated for dissolution and drug release properties using hydrochlorothiazide as a model drug. The effect of storage of GRF inside hard gelatin capsules on rate of swelling of the capsule shell and release
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hypotensive agents – Pharmacokinetics"

1

LC, Dutta. "Chapter-75 Pharmacognosy and Pharmacokinetics of Ocular Hypotensive Agents." In Modern Ophthalmology Vol 1 Vol 2 &amp Vol 3. Jaypee Brothers Medical Publishers (P) Ltd., 2005. http://dx.doi.org/10.5005/jp/books/10535_75.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hypotensive agents – Pharmacokinetics' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography